NexImmune Inc (NEXI)
0.3235
+0.10
(+46.31%)
USD |
OTCM |
Nov 14, 15:14
NexImmune Total Liabilities (Quarterly): 4.941M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.941M |
| March 31, 2024 | 6.024M |
| December 31, 2023 | 5.084M |
| September 30, 2023 | 6.308M |
| June 30, 2023 | 6.472M |
| March 31, 2023 | 7.086M |
| December 31, 2022 | 10.76M |
| September 30, 2022 | 9.959M |
| June 30, 2022 | 9.813M |
| Date | Value |
|---|---|
| March 31, 2022 | 7.921M |
| December 31, 2021 | 7.271M |
| September 30, 2021 | 7.432M |
| June 30, 2021 | 5.483M |
| March 31, 2021 | 6.105M |
| December 31, 2020 | 27.06M |
| September 30, 2020 | 15.93M |
| December 31, 2019 | 3.107M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.107M
Minimum
Dec 2019
27.06M
Maximum
Dec 2020
8.632M
Average
7.086M
Median
Mar 2023
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp | 15.60M |
| AIM ImmunoTech Inc | 9.613M |
| IGC Pharma Inc | 2.714M |
| NovaBay Pharmaceuticals Inc | 4.542M |
| Protalix BioTherapeutics Inc | 62.96M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.861M |
| Shareholders Equity (Quarterly) | 0.9205M |